The company is currently investing in more than 58 active best-of-field projects in 7 countries.
Biogenum (ISIN: KR7013369996), a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, is pleased to announce that it is partnering with Hong Kong Medical University to study brain aging and dementia in 300 individu...